Company Overview
History
April 2019.
October 2019.
July 2020.
May 2021.
November 2021.
December 2021.
January 2022.
NEURORIVE
Find your Happiness. Again.
Neurorive develops rapid-acting antidepressants and cognitive enhancers based on improving brain plasticity and reducing neuroinflammation.
Neurorive aims to become a powerful drug screening platform through the development of new drugs along with neurophysiology and brain science.
Neurorive has been developing a new drug for central neurological and psychiatric diseases since its establishment in 2019.
Starting with the development of treatments for dementia and depression, we are also building a lineup of new PTSD drugs.
April 2019.
October 2019.
July 2020.
May 2021.
November 2021.
December 2021.
January 2022.
Found Neurorive Inc.
Selected by TIPS (Operator : Korea university holdings)
Invested Series A 5.5 Billion (Common stock, post value 34Billion)
Selected Young Unicorn, Register two antidepressant patents
Register five anti-dementia and nine patents domestic and foreign
Antidepressant enter clinical test
Anti-dementia enter clinical test